Eli Lilly Archives - Lets Talk Health

Analysis: Drug industry bets on new blockbusters in 2013

01/15/2013 majac Your Health Matters

LONDON/NEW YORK (Reuters) – Drugmakers are betting that a new wave of medicines for cancer, diabetes, heart disease, multiple sclerosis and hepatitis will shape up as tomorrow's blockbusters in the coming 12 months. With the industry regaining some of its swagger after winning 39 new drug approvals last year – a record only beaten in 1996 – there are signs the improving trend could continue through 2013. Roche, GlaxoSmithKline, Eli Lilly, Biogen Idec, Gilead Sciences and Novo Nordisk are among those with important new products reaching a critical point in development this year. …

Biogen Idec, Eli Lilly, Gilead Sciences, Novo Nordisk

Eli Lilly settles Mass. pregnancy drug-cancer case

01/10/2013 majac Your Health Matters

BOSTON (AP) — Eli Lilly and Co. has settled a lawsuit brought by four sisters who contended their breast cancer was caused by a drug their mother took during pregnancy in the 1950s, a move some believe could trigger financial settlements in scores of other claims brought by women around the country.

Eli Lilly

APNewsBreak: Deal in Mass. suit on pregnancy drug

01/09/2013 majac Your Health Matters

BOSTON (AP) — Four sisters who claimed their breast cancer was caused by a drug their mother took during pregnancy in the 1950s reached a settlement Wednesday with Eli Lilly and Co. in the first of scores of similar claims around the country to go to trial.

Eli Lilly

APNewsBreak: Settlement in suit on pregnancy drug

01/09/2013 majac Your Health Matters

BOSTON (AP) — Four sisters who claimed in a lawsuit their breast cancer was caused by synthetic estrogen their mother took during pregnancy in the 1950s have reached a settlement with the drug company Eli Lilly and Co., a lawyer for the sisters said Wednesday.

Eli Lilly

Eli Lilly banks on cost controls for higher 2013 profit

01/04/2013 majac Your Health Matters

(Reuters) – Eli Lilly and Co said on Friday it expects profit in 2013 to increase by more than Wall Street had been forecasting, primarily due to cost controls and improved productivity. Lilly, whose shares were up nearly 4 percent on Friday, said 2013 sales will be flat to a bit higher, despite the loss of patent on its $5 billion-a-year antidepressant, Cymbalta, in December. The Indianapolis-based drugmaker is coming off a particularly difficult 2012 when sales declined sharply because of competition from cheaper generics. It expects 2013 earnings to increase to $3.75 to $3. …

Eli Lilly, Wall Street